Evidence map›Paper›PMID 40767293›Full record

ReviewJournal of the American Heart Association2025

Advancements and Perspectives in the Bioprosthetic Heart Valve: A Comprehensive Review on Biomaterial Processing and Emerging Polymeric Materials.

Hanluo Li, Shenghua Li, Yalan Lei, Ming Sun, Chunlin Wu, Xueli Wang, Shiwen Xiong, Qing Wang, Sini Kang, Song Chen and 1 more

Abstract readReview
In one paragraph

Review in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Innovation and Challenges in Materials for Transcatheter Aortic Valves.Journal of cardiovascular translational research · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Impact of lipoprotein(a) on the durability of aortic bioprosthetic valves.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanluo LiNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.
Shenghua LiNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.ORCID 0009-0009-7773-0531
Yalan LeiNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.
Ming SunHubei Provincial Enterprise Technology Center, Wuhan Vickor Medical Technology Co. Wuhan China.
Chunlin WuHubei Provincial Enterprise Technology Center, Wuhan Vickor Medical Technology Co. Wuhan China.
Xueli WangHubei Provincial Enterprise Technology Center, Wuhan Vickor Medical Technology Co. Wuhan China.
Shiwen XiongNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.
Qing WangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.
Sini KangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.ORCID 0009-0000-0255-7775
Song ChenNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.
Xiaoke ShangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), School of Life and Health Sciences, Hubei University of Technology Wuhan China.ORCID 0009-0007-3901-0088

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart valve disease contributes to cardiovascular disease-associated death. Bioprosthetic heart valves have emerged as a preferred option for heart valve replacement due to their superior hemodynamic performance and reduced need for lifelong anticoagulation. However, their long-term durability is compromised by calcification, immunogenicity, and structural degeneration, primarily due to glutaraldehyde fixation and residual xenogeneic antigens. This review highlights recent advances in biomaterial optimization, with an emphasis on decellularization and cross-linking strategies aimed at improving the mechanical stability and biocompatibility of bioprosthetic heart valves. The effectiveness and limitations of various decellularization agents, including nonionic, ionic, and amphoteric detergents, are critically evaluated, alongside novel cross-linking reagents such as ribose, genipin, and polyphenols. Furthermore, the development of polymeric heart valves and nanocomposite materials is also explored as a means to address the limitations of conventional mechanical and bioprosthetic valves. Emerging strategies involving gene-editing technologies, stem cell therapies, and tissue engineering hold considerable promise for the development of next-generation, patient-specific, and immunotolerant heart valve prostheses. Collectively, these innovations are driving a paradigm shift toward long-lasting, bioactive, and regenerative heart valve replacements.

Indexed as

Biocompatible MaterialsBioprosthesisHeart Valve DiseasesHeart Valve ProsthesisHeart Valve Prosthesis ImplantationPolymersAnimalsHumansProsthesis DesignTissue EngineeringBiocompatible MaterialsPolymersbiological heart valvesbiomaterialscrosslinkingdecellularizationheart valve tissue engineeringpolymeric heart valves

Identifiers

PMID40767293
PMCPMC12533660

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.